Poly(Lactic-Co-Glycolic Acid) (PLGA) Market 2026: Market Leaders Powering Global Biomedical Innovation

MARKET INSIGHTS

Global Poly(Lactic-Co-Glycolic Acid) (PLGA) market size was valued at USD 75.3 million in 2024. The market is projected to grow from USD 77.1 million in 2025 to USD 92.4 million by 2032, exhibiting a CAGR of 2.6% during the forecast period.

PLGA is a biocompatible and biodegradable copolymer composed of lactic acid and glycolic acid monomers. This FDA‑approved polymer is widely used in pharmaceutical and medical applications due to its controlled degradation properties, making it ideal for drug delivery systems, medical implants, and tissue engineering scaffolds. The material can be formulated into various structures including nanoparticles, microparticles, and 3D‑printed matrices.

The market growth is driven by increasing adoption of biodegradable materials in healthcare, rising demand for targeted drug delivery systems, and expanding applications in regenerative medicine. While North America currently dominates the market, Asia‑Pacific is expected to witness the fastest growth due to expanding healthcare infrastructure. Recent developments include Evonik’s 2023 expansion of its PLGA production capacity in Germany to meet growing demand for implantable drug delivery devices.

Poly(Lactic-Co-Glycolic Acid) (PLGA) Market – View in Detailed Research Report

Market Size and Forecast

Base Year 2025: USD 77.1 million
Estimated 2026: USD 78.5 million
Projected 2034: USD 92.4 million

Product Definition

PLGA is a copolymer of lactic acid and glycolic acid that offers tunable degradation rates, allowing manufacturers to design drug release profiles from weeks to months. Its FDA approval and proven biocompatibility make it a preferred material for a range of medical devices, including drug‑eluting stents, bone screws, and injectable microspheres.

Top 10 Companies in the PLGA Market

🔟 1. BASF SE

Headquarters: Ludwigshafen, Germany
Key Offering: PLGA copolymers for drug delivery and tissue engineering

BASF has a long history of polymer research and has scaled its PLGA production to support both small‑molecule and biologic drug delivery platforms. The company’s advanced process controls ensure consistent molecular weight distribution, a critical factor for predictable degradation.

Sustainability & Growth Initiatives:

• Investment in renewable feedstock sourcing for lactic acid production
• Partnerships with academic institutions to develop next‑generation biodegradable scaffolds
• Expansion of production capacity in Europe to meet rising demand for implantable devices

🟨 2. Evonik Industries AG

Headquarters: Essen, Germany
Key Offering: High‑purity PLGA grades for controlled‑release systems

Evonik’s recent capacity expansion in 2023 positioned the company to supply the growing segment of implantable drug delivery devices. Its focus on process optimization has reduced batch variability, enhancing product reliability for medical applications.

Sustainability & Growth Initiatives:

• Development of bio‑based monomer synthesis routes
• Collaboration with pharmaceutical companies to launch extended‑release formulations
• Implementation of circular economy practices in polymer manufacturing

🟨 3. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: PLGA‑based drug delivery systems for oncology and chronic disease

Merck leverages its strong R&D portfolio to integrate PLGA into multi‑modal therapies, offering sustained release of chemotherapeutics and biologics. The company’s focus on precision medicine aligns with the trend toward patient‑specific drug regimens.

Sustainability & Growth Initiatives:

• Research into biodegradable polymer blends to enhance mechanical performance
• Investment in digital manufacturing platforms for real‑time process control
• Strategic alliances with biotech firms to co‑develop PLGA‑based therapeutics

🟨 4. Durect Corporation

Headquarters: San Diego, USA
Key Offering: PLGA‑based drug delivery devices for ophthalmology and cardiovascular applications

Durect’s expertise in implantable drug delivery has enabled it to launch several PLGA‑based products that reduce dosing frequency and improve patient adherence. The company’s R&D pipeline focuses on expanding into new therapeutic areas such as neuro‑degenerative disorders.

Sustainability & Growth Initiatives:

• Partnerships with device manufacturers to integrate PLGA into next‑generation implants
• Adoption of green chemistry practices in polymer synthesis
• Development of biodegradable coatings for drug‑eluting stents

🟨 5. Jinan Daigang Biomaterial Co., Ltd.

Headquarters: Jinan, China
Key Offering: PLGA nanoparticles and microspheres for vaccine and biologic delivery

China’s rapid expansion in pharmaceutical manufacturing has positioned Jinan Daigang as a key supplier of PLGA products for both domestic and export markets. The company’s focus on scalable production processes supports its growth strategy in emerging markets.

Sustainability & Growth Initiatives:

• Investment in high‑efficiency polymerization reactors
• Collaboration with local universities to develop biodegradable material curricula
• Expansion of production facilities to meet Asia‑Pacific demand

🟨 6. CarbioTech

Headquarters: Madrid, Spain
Key Offering: PLGA‑based scaffolds for tissue engineering and regenerative medicine

CarbioTech has carved a niche in regenerative applications, offering customizable scaffold designs that match patient‑specific anatomical requirements. Its research collaborations focus on integrating growth factors into PLGA matrices to accelerate tissue regeneration.

Sustainability & Growth Initiatives:

• Development of bio‑inspired polymer blends to improve mechanical properties
• Implementation of closed‑loop manufacturing to reduce waste
• Partnerships with medical device firms to launch combinatorial products

🟨 7. Akina Inc.

Headquarters: San Jose, USA
Key Offering: PLGA‑based drug delivery systems for ophthalmic and systemic therapies

Akina’s focus on ophthalmic drug delivery has led to the launch of several PLGA‑based implants that provide sustained release of anti‑VEGF agents. The company’s pipeline also explores PLGA for oral and injectable biologics.

Sustainability & Growth Initiatives:

• Use of renewable raw materials for polymer synthesis
• Collaboration with global health organizations to expand access in low‑income regions
• Adoption of digital twin technology for process optimization

🟨 8. Medtronic plc

Headquarters: Dublin, Ireland
Key Offering: PLGA‑based implantable devices for cardiovascular and orthopedic applications

Medtronic’s extensive portfolio of implantable devices has been enhanced by incorporating PLGA into drug‑eluting stents and bioresorbable fixation systems. The company’s global reach facilitates rapid deployment of PLGA technologies across diverse markets.

Sustainability & Growth Initiatives:

• Investment in biodegradable polymer research to reduce device footprint
• Partnerships with material scientists to develop high‑performance PLGA blends
• Expansion of manufacturing hubs in emerging economies

🟨 9. Jiangsu Hengrui Medicine Co., Ltd.

Headquarters: Jiangsu, China
Key Offering: PLGA microspheres for controlled release of small molecules and biologics

Jiangsu Hengrui’s focus on oncology and chronic disease therapeutics aligns with the growing need for sustained drug delivery. The company’s PLGA platform supports its pipeline of novel anti‑cancer agents.

Sustainability & Growth Initiatives:

• Development of low‑cost PLGA production processes for generic markets
• Collaboration with global pharma partners to co‑develop PLGA formulations
• Implementation of eco‑friendly packaging solutions for drug delivery products

🟨 10. BioXcell

Headquarters: Seoul, South Korea
Key Offering: PLGA‑based bio‑ink for 3D bioprinting and tissue scaffolds

BioXcell’s innovations in 3D bioprinting have positioned it as a leader in the emerging field of bio‑ink development. Its PLGA‑based formulations provide high cell viability and support vascularization in printed constructs.

Sustainability & Growth Initiatives:

• Research into bio‑based polymer blends to enhance printability
• Partnerships with research institutions to develop organ‑on‑a‑chip platforms
• Expansion of production capacity to meet global demand for bioprinting materials

Download FREE Sample Report

Get Full Report

Outlook

The PLGA market is expected to maintain a steady trajectory as healthcare providers seek materials that combine biocompatibility with precise drug release. The shift toward patient‑centric therapies and the need for implantable devices that eliminate secondary surgeries will continue to support demand. Emerging markets, particularly in Asia‑Pacific, are likely to contribute a disproportionate share of growth as local manufacturing capabilities mature.

Future Trends

• Integration of PLGA with nanotechnology to create sub‑200 nm carriers for targeted oncology therapies.
• Expansion of 3D bioprinting applications, leveraging PLGA bio‑inks to produce vascularized tissue constructs.
• Development of smart PLGA formulations that respond to physiological triggers, such as pH or enzyme levels, to release therapeutics on demand.
• Increased collaboration between polymer manufacturers and biologic drug developers to create combination products that streamline regulatory approval.